SARS CoV-2 infection among patients using immunomodulatory therapies

Kevin L Winthrop; Amanda E Brunton; Susan Beekmann; Philip Polgreen; John Baddley; Kenneth G Saag; Cassandra Calabrese; Leonard Calabrese; Philip C Robinson; Zachary S Wallace; Jeffrey R Curtis; COVID-19 Study Team

doi:10.1136/annrheumdis-2020-218580

Back

SARS CoV-2 infection among patients using immunomodulatory therapies

Letter/Communication

Open access

SARS CoV-2 infection among patients using immunomodulatory therapies

Kevin L Winthrop, Amanda E Brunton, Susan Beekmann, Philip Polgreen, John Baddley, Kenneth G Saag, Cassandra Calabrese, Leonard Calabrese, Philip C Robinson, Zachary S Wallace, …

Annals of the rheumatic diseases, Vol.80(2), pp.269-271

02/2021

DOI: 10.1136/annrheumdis-2020-218580

PMID: 32759259

Files and links (1)

url

https://doi.org/10.1136/annrheumdis-2020-218580View

Published (Version of record) Open Access

Abstract

Adolescent

Adult

Aged

Aged, 80 and over

Anti-Bacterial Agents - therapeutic use

Antibodies, Monoclonal, Humanized - therapeutic use

Antirheumatic Agents - therapeutic use

Arthritis, Rheumatoid - complications

Arthritis, Rheumatoid - drug therapy

Autoimmune Diseases - complications

Autoimmune Diseases - drug therapy

Azithromycin - therapeutic use

Biological Products - therapeutic use

COVID-19 - complications

COVID-19 - drug therapy

COVID-19 - mortality

COVID-19 - therapy

Enzyme Inhibitors - therapeutic use

Female

Glucocorticoids - therapeutic use

Hospitalization

Humans

Hydroxychloroquine - therapeutic use

Immunomodulation

Immunosuppressive Agents - therapeutic use

Inflammatory Bowel Diseases - complications

Inflammatory Bowel Diseases - drug therapy

Intensive Care Units

Janus Kinase Inhibitors - therapeutic use

Male

Middle Aged

Respiration, Artificial

Sarcoidosis - complications

Sarcoidosis - drug therapy

SARS-CoV-2

Surveys and Questionnaires

Tumor Necrosis Factor Inhibitors - therapeutic use

Young Adult

Details

Title: Subtitle: SARS CoV-2 infection among patients using immunomodulatory therapies
Creators: Kevin L Winthrop - Oregon Health & Science University
Amanda E Brunton - Oregon Health & Science University
Susan Beekmann - University of Iowa
Philip Polgreen - University of Iowa
John Baddley - University of Maryland, Baltimore
Kenneth G Saag - University of Alabama at Birmingham
Cassandra Calabrese - Cleveland Clinic
Leonard Calabrese - Cleveland Clinic
Philip C Robinson - The University of Queensland
Zachary S Wallace - Massachusetts General Hospital
Jeffrey R Curtis - University of Alabama at Birmingham
COVID-19 Study Team
Resource Type: Letter/Communication
Publication Details: Annals of the rheumatic diseases, Vol.80(2), pp.269-271
DOI: 10.1136/annrheumdis-2020-218580
PMID: 32759259
NLM abbreviation: Ann Rheum Dis
ISSN: 0003-4967
eISSN: 1468-2060
Grant note: UL1 TR002537 / NCATS NIH HHS
Language: English
Date published: 02/2021
Academic Unit: Infectious Diseases; Epidemiology; Injury Prevention Research Center; Internal Medicine
Record Identifier: 9984359802602771

Metrics

23 Record Views

24 Times Cited - Web of Science

See more details